Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19)

JAMA Cardiol. 2020 Sep 1;5(9):988-990. doi: 10.1001/jamacardio.2020.1874.

Authors

Laine E Thomas^{1

2

3}, Robert O Bonow^{4

5}, Michael J Pencina^{1

2

6}

Affiliations

¹ Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Durham, North Carolina.
³ Assistant Editor.
⁴ Northwestern University Feinberg School of Medicine, Chicago, Illinois.
⁵ Editor.
⁶ Deputy Editor.

PMID: 32936260
DOI: 10.1001/jamacardio.2020.1874

No abstract available

Publication types

Editorial
Comment

MeSH terms

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Betacoronavirus
COVID-19
Coronavirus Infections*
Coronavirus*
Humans
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors